Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

p62 anti-cancer DNA vaccine - CureLab Oncology

Next Previous
X
Search
Drug Profile

p62 anti-cancer DNA vaccine - CureLab Oncology

Alternative Names: Elenagen; p62DNA

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureLab Oncology
  • Class Antineoplastics; Cancer vaccines; DNA vaccines
  • Mechanism of Action Autophagy stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Clinical Phase Unknown Ovarian cancer; Triple negative breast cancer
  • Preclinical Alzheimer's disease
  • No development reported Age-related macular degeneration

Most Recent Events

  • 30 Nov 2023 CureLab plans a phase II/III trial for Ovarian cancer (Adjuvant therapy) in USA (IM, Injection)
  • 02 Mar 2023 CureLab plans clinical trials for Triple-negative breast cancer and platinum-resistant Ovarian cancer in 2023
  • 28 Nov 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (IM, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top